Yabao Pharmaceutical Group Co., Ltd (SHA:600351)
6.09
+0.05 (0.83%)
Apr 30, 2025, 3:00 PM CST
SHA:600351 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 2,686 | 2,880 | 2,681 | 2,681 | 2,556 | Upgrade
|
Other Revenue | - | 29.46 | 37.45 | 83.2 | 46.85 | Upgrade
|
Revenue | 2,686 | 2,910 | 2,718 | 2,764 | 2,602 | Upgrade
|
Revenue Growth (YoY) | -7.69% | 7.05% | -1.66% | 6.21% | -14.45% | Upgrade
|
Cost of Revenue | 1,298 | 1,246 | 1,216 | 1,095 | 1,073 | Upgrade
|
Gross Profit | 1,388 | 1,664 | 1,502 | 1,669 | 1,529 | Upgrade
|
Selling, General & Admin | 920.93 | 1,228 | 1,159 | 1,296 | 1,235 | Upgrade
|
Research & Development | 139.52 | 118.29 | 130.62 | 157.13 | 144.46 | Upgrade
|
Other Operating Expenses | -11.39 | 31.34 | 33.98 | 33.38 | 34.31 | Upgrade
|
Operating Expenses | 1,049 | 1,373 | 1,324 | 1,473 | 1,412 | Upgrade
|
Operating Income | 339.12 | 291.5 | 178.07 | 196.65 | 117.42 | Upgrade
|
Interest Expense | - | -12.3 | -18.77 | -22.61 | -32.61 | Upgrade
|
Interest & Investment Income | - | 9.49 | 8.18 | 22.04 | 4 | Upgrade
|
Currency Exchange Gain (Loss) | - | -0.03 | 0.27 | -0.13 | -0.17 | Upgrade
|
Other Non Operating Income (Expenses) | -2.16 | -3.14 | -8.01 | -3.53 | -4.24 | Upgrade
|
EBT Excluding Unusual Items | 336.96 | 285.52 | 159.74 | 192.42 | 84.4 | Upgrade
|
Impairment of Goodwill | - | - | -48.3 | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | -3.04 | -5.35 | -4.17 | 1.34 | 3.34 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.35 | 1.14 | 0.12 | 0.15 | 2.63 | Upgrade
|
Asset Writedown | -42.16 | -84.97 | -9.75 | -22.97 | -3.44 | Upgrade
|
Other Unusual Items | - | 22.63 | 28.02 | 30.66 | 40.49 | Upgrade
|
Pretax Income | 292.11 | 218.98 | 125.65 | 201.59 | 127.42 | Upgrade
|
Income Tax Expense | 68.19 | 39.07 | 21.04 | 17.83 | 18.43 | Upgrade
|
Earnings From Continuing Operations | 223.92 | 179.91 | 104.6 | 183.76 | 108.99 | Upgrade
|
Minority Interest in Earnings | 18.77 | 19.67 | 0.05 | 3.33 | -1.62 | Upgrade
|
Net Income | 242.69 | 199.59 | 104.66 | 187.09 | 107.37 | Upgrade
|
Net Income to Common | 242.69 | 199.59 | 104.66 | 187.09 | 107.37 | Upgrade
|
Net Income Growth | 21.60% | 90.71% | -44.06% | 74.25% | 672.05% | Upgrade
|
Shares Outstanding (Basic) | 723 | 763 | 770 | 770 | 770 | Upgrade
|
Shares Outstanding (Diluted) | 723 | 763 | 770 | 770 | 770 | Upgrade
|
Shares Change (YoY) | -5.25% | -0.89% | 0.02% | -0.04% | -0.86% | Upgrade
|
EPS (Basic) | 0.34 | 0.26 | 0.14 | 0.24 | 0.14 | Upgrade
|
EPS (Diluted) | 0.34 | 0.26 | 0.14 | 0.24 | 0.14 | Upgrade
|
EPS Growth | 28.34% | 92.42% | -44.07% | 74.32% | 678.77% | Upgrade
|
Free Cash Flow | 437.03 | 397.7 | 398.23 | 342.45 | 318.09 | Upgrade
|
Free Cash Flow Per Share | 0.60 | 0.52 | 0.52 | 0.45 | 0.41 | Upgrade
|
Dividend Per Share | - | 0.150 | 0.050 | 0.080 | 0.050 | Upgrade
|
Dividend Growth | - | 200.00% | -37.50% | 60.00% | 150.00% | Upgrade
|
Gross Margin | 51.68% | 57.19% | 55.27% | 60.39% | 58.77% | Upgrade
|
Operating Margin | 12.63% | 10.02% | 6.55% | 7.12% | 4.51% | Upgrade
|
Profit Margin | 9.04% | 6.86% | 3.85% | 6.77% | 4.13% | Upgrade
|
Free Cash Flow Margin | 16.27% | 13.67% | 14.65% | 12.39% | 12.22% | Upgrade
|
EBITDA | 475.46 | 446.52 | 338.04 | 363.93 | 287.3 | Upgrade
|
EBITDA Margin | 17.70% | 15.35% | 12.44% | 13.17% | 11.04% | Upgrade
|
D&A For EBITDA | 136.34 | 155.02 | 159.97 | 167.27 | 169.88 | Upgrade
|
EBIT | 339.12 | 291.5 | 178.07 | 196.65 | 117.42 | Upgrade
|
EBIT Margin | 12.63% | 10.02% | 6.55% | 7.12% | 4.51% | Upgrade
|
Effective Tax Rate | 23.34% | 17.84% | 16.75% | 8.85% | 14.46% | Upgrade
|
Revenue as Reported | - | 2,910 | 2,718 | 2,764 | 2,602 | Upgrade
|
Advertising Expenses | - | 119.53 | 105.5 | 100.49 | 92.83 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.